Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.50 |
| ▸ | PABPC1 | P11940 | 2/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.49 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 10/20 | 0.48 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 9/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | PIP4K2A | P48426 | 2/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9929561 | 0.80 | SCN9A (0.56) | MEN1KMT2ASCN9ACDK1CCNB1 | |
| SCHEMBL10187337 | 0.80 | MEN1 (0.81) | MEN1KMT2ASCN9ACDK1CCNB1 | |
| SCHEMBL1094522 | 0.79 | SCN9A (0.58) | MEN1KMT2ASCN9ACDK1CCNB1 | |
| SCHEMBL13472418 | 0.79 | KMO (0.56) | MEN1KMT2APABPC1PIK3CANPC1 | |
| SCHEMBL1097149 | 0.78 | MEN1 (0.78) | MEN1KMT2ASCN9ACDK1CCNB1 | |
| SCHEMBL29636514 | 0.78 | KMT2A (0.55) | MEN1KMT2APABPC1PIK3CGPIK3CA | |
| SCHEMBL14127702 | 0.78 | KMT2A (0.55) | MEN1KMT2APABPC1PIK3CGPIK3CA | |
| SCHEMBL27606990 | 0.77 | MEN1 (0.57) | MEN1KMT2APABPC1PIK3CGPIK3CA | |
| SCHEMBL13288393 | 0.74 | MAPT (0.67) | PIK3CGPIK3CAPIK3CDPIK3CBRAB9A | |
| SCHEMBL1013630 | 0.74 | ABL1 (0.62) | MEN1KMT2ANPC1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2418205-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-8552002-B2 | 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-[6-(2,6-dimethyl-pyridin-3-ylamino)-pyrimidin-4-yl]-1-methyl-urea; 3-(2,6-Dichloro-3,5-dimethoxy-phenyl)-1-methyl-1-{6-[4-(4-methyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-urea | NOVARTIS AG (CH) | 2013-10-08 | — | — | US | disclosed |
| EP-2409969-B1 | Pyrimidine urea derivatives as kinase inhibitors | NOVARTIS AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | DING QIANG (CN) | 2013-01-10 | — | — | US | disclosed |
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2013-01-10 | — | — | US | disclosed |
| EP-2418205-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-02-15 | — | — | EP | disclosed |
| EP-2409969-A1 | Pyrimidine urea derivatives as kinase inhibitors | Novartis AG (CH) | 2012-01-25 | — | — | EP | disclosed |
| EP-1761505-B1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2009-05-28 | — | — | US | disclosed |
| EP-1761505-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | Novartis AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006000420-A1 | PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130012476-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | MEN1 559/4885KMT2A 1867/4885SCN9A 3110/4885 |
| US-20130012704-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K1, CDK1 | MEN1 559/4885KMT2A 1867/4885SCN9A 3110/4885 |
| US-20090137804-A1 | Compounds and Compositions as Protein Kinase Inhibitors | MAP3K20, MAP3K1, CDK1 | MEN1 559/4885KMT2A 1867/4885SCN9A 3110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.